Investor Relations

Press Releases

All Releases
View Summary OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition
Jul 2, 2015
PDF 18.5 KB
View Summary Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Jul 1, 2015
PDF 11.0 KB
View Summary OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Jun 26, 2015
PDF 12.9 KB
View Summary OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa
Jun 9, 2015
PDF 14.1 KB
View Summary OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger
Jun 8, 2015
PDF 21.7 KB
View Summary OPKO Health to Acquire Bio-Reference Laboratories
Jun 4, 2015
PDF 22.4 KB
View Summary OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration
May 29, 2015
PDF 13.6 KB
View Summary OPKO Health to Present at the Jefferies 2015 Healthcare Conference
May 27, 2015
PDF 9.1 KB
View Summary OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting
May 18, 2015
PDF 13.1 KB
View Summary OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large Community-Based Referral Cohort
May 15, 2015
PDF 13.2 KB
View Summary OPKO Announces First Quarter Operating and Financial Results
May 11, 2015
PDF 72.9 KB
View Summary CORRECTING and REPLACING OPKO To Announce First Quarter Financial Results on May 11, 2015
May 7, 2015
PDF 10.5 KB
View Summary OPKO To Announce First Quarter Financial Results on May 11, 2015
May 7, 2015
PDF 10.3 KB
View Summary OPKO Health Acquires EirGen Pharma
May 5, 2015
PDF 12.1 KB
View Summary OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test
Apr 21, 2015
PDF 61.6 KB
View Summary Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes
Apr 1, 2015
PDF 10.2 KB
View Summary Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
Mar 27, 2015
PDF 12.9 KB
View Summary OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources
Mar 23, 2015
PDF 11.1 KB
View Summary OPKO Lab Receives Accreditation From College of American Pathologists
Mar 18, 2015
PDF 13.3 KB
View Summary Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference
Mar 6, 2015
PDF 12.7 KB
Showing 1-20 of 224 Page: 1 2 3 4 5 ... 12  Next 20